Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development ProgramsFinancing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors.

Zenas BioPharma宣布增加2亿美元的C系列融资，以推进由SR One，NEA，Norwest Venture Partners和Delos Capital领导的以免疫学为重点的中晚期临床开发计划，Enavate Sciences，Longitude Capital以及其他新的和现有投资者的大力参与。

Proceeds to support ongoing mid- to late-stage clinical development programs for Company’s lead I&I product candidate, obexelimabWALTHAM, Mass., May 7, 2024-- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, today announced the closing of an upsized $200 million Series C preferred stock financing.

2024年5月7日，为公司的主要I＆I候选产品obexelimabWALTHAM（马萨诸塞州）正在进行的中晚期临床开发计划提供资金支持——Zenas BioPharma是一家致力于成为炎症和免疫导向疗法开发和商业化领军者的全球生物制药公司，今天宣布关闭价值2亿美元的C系列优先股融资。

The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Additional new investors, the Federated Hermes Kaufmann Funds, and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital participated in the financing.

融资回合由SR One、NEA、Norwest Venture Partners和Delos Capital牵头，Enavate Sciences和Longitude Capital参与了这一轮融资。其他新投资者、联邦Hermes Kaufmann基金和Arrowmark Partners，以及现有投资者Fairmount、惠灵顿管理公司、Rock Springs Capital、Pivotal bioVenture Partners、Vivo Capital、Quan Venture Fund和Superstring Capital参与了融资。

In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors..

在融资的同时，SR One的风险合伙人杰克·纳恩（JakeNunn）和德洛斯资本（Delos Capital）的合伙人蒂姆·肖（TimXiao）加入了泽纳斯的董事会。。

Proceeds will support ongoing mid- to late-stage clinical development programs for the Company’s lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit the activity of B cells, plasmablasts, and CD19-expressing plasma cells.

收益将支持该公司主要候选产品obexelimab正在进行的中晚期临床开发计划，obexelimab是一种双功能单克隆抗体，旨在结合CD19和FcγRIIb以抑制B细胞，浆母细胞和表达CD19的浆细胞的活性。

The obexelimab clinical programs include an ongoing Phase 3 registration-directed trial in IgG4-Related Disease, two planned Phase 2 randomized controlled trials in Multiple Sclerosis and Systemic Lupus Erythematosus, and an ongoing open label Phase 2 trial in Warm Autoimmune Hemolytic Anemia.

obexelimab临床计划包括正在进行的IgG4相关疾病的3期注册指导试验，两项计划的多发性硬化症和系统性红斑狼疮的2期随机对照试验，以及正在进行的温热自身免疫性溶血性贫血的开放标签2期试验。

“We are pleased and appreciative of the support we have received from this group of tremendous life sciences investors as we advance the ongoing obexelimab development program across multiple auto-immune diseases,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Their commitment to Zenas is a testament to our vision to be a global leader in bringing innovative immunology-based therapies to patients around the world.

Zenas BioPharma创始人兼首席执行官朗尼·莫勒（LonnieMoller）表示：“我们很高兴并感谢这群巨大的生命科学投资者的支持，因为我们正在推进针对多种自身免疫疾病的奥贝昔单抗开发计划。”。“他们对Zenas的承诺证明了我们的愿景，即成为全球领先者，为世界各地的患者带来基于免疫学的创新疗法。

This financing enables us to complete multiple potentially value driving clinical programs.”.

这种融资使我们能够完成多个潜在的价值驱动临床项目。”。

“We are excited to support Zenas’ continued progress toward its goal of becoming a global leader in innovative immunology-based therapies, and we are confident in the capabilities of this exceptional team to advance the comprehensive development program for obexelimab across multiple potential indications,” said Jake Nunn, venture partner at SR One.

SR One的风险合伙人Jake Nunn说：“我们很高兴支持Zenas在成为基于免疫学的创新疗法的全球领导者这一目标上不断取得进展，我们对这支杰出团队的能力充满信心，能够跨多种潜在适应症推进奥贝西单抗的综合开发计划。”。

“At SR One, we invest in companies like Zenas whose science has the potential to rewrite the medical textbooks and meaningfully transform patient care. We are proud to serve as lead investor alongside an exceptional syndicate and look forward to supporting Zenas in advancing a pipeline of innovative new therapeutic approaches for patients living with inflammatory and immune-mediated diseases.”.

“在SR One，我们投资了像Zenas这样的公司，这些公司的科学有可能改写医学教科书，并有意义地改变患者护理。我们很自豪能与一个特殊的财团一起作为首席投资者，并期待着支持Zenas为炎症和免疫介导疾病患者推进创新的新治疗方法。”。

About Obexelimab

关于Obexelimab

Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit B-lineage cell activity. Obexelimab has demonstrated clinical activity and was well-tolerated in five clinical trials, including in several autoimmune diseases, in which 198 subjects were dosed. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases.

Obexelimab是一种双功能单克隆抗体，旨在结合CD19和FcγRIIb以抑制B谱系细胞活性。Obexelimab已显示出临床活性，并且在五项临床试验中耐受性良好，包括在几种自身免疫性疾病中，其中198名受试者服用了该药。在这些临床研究中，奥贝昔单抗显示出抑制B细胞功能而不消耗细胞，从而对各种自身免疫性疾病患者产生了令人鼓舞的治疗效果。

Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc. Obexelimab is currently being studied in a global Phase 3 clinical study in patients with IgG4-Related Disease and a global Phase 2/3 study in patients with Warm Autoimmune Hemolytic Anemia (wAIHA). Clinical development of obexelimab for Multiple Sclerosis and Systemic Lupus Erythematosus is under way.

Zenas从Xencor，Inc.获得了obexelimab的全球独家权利。obexelimab目前正在进行IgG4相关疾病患者的全球3期临床研究和温热自身免疫性溶血性贫血（wAIHA）患者的全球2/3期研究。obexelimab治疗多发性硬化症和系统性红斑狼疮的临床开发正在进行中。

.

.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4-Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 2/3 (SApHiAre) study for the treatment of wAIHA is available at clinicaltrials.gov: NCT05786573.

有关治疗IgG4相关疾病的3期（INDIGO）研究的更多信息，请访问clinicaltrials.gov:NCT05662241。有关治疗wAIHA的2/3期（SApHiAre）研究的更多信息，请访问clinicaltrials.gov:NCT05786573。

About Zenas BioPharma

关于Zenas BioPharma

Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need.

Zenas BioPharma是一家临床阶段的全球生物制药公司，致力于成为全球有需要的患者炎症和免疫学（I＆I）指导疗法开发和商业化的领导者。凭借全球临床开发能力和运营，Zenas正在高度未满足医疗需求的领域推进一系列潜在分化的自身免疫疗法。

Zenas’ experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn..

Zenas经验丰富的领导团队和商业合作伙伴网络推动卓越运营，提供潜在的变革性疗法，以改善面临自身免疫和罕见疾病的患者的生活。有关Zenas BioPharma的更多信息，请访问www.zenasbio.com，并通过X关注我们@ZenasBioPharma和LinkedIn。。

About SR One

关于SR One

SR One is a transatlantic biotechnology venture capital firm that collaborates with entrepreneurs and investment partners in an effort to build elite biotechnology companies. The Company’s mission is to translate innovative technologies and scientific discoveries into next-generation medicines with the potential to benefit patients with significant unmet medical needs.

SR One是一家跨大西洋生物技术风险投资公司，与企业家和投资伙伴合作，努力建立精英生物技术公司。该公司的使命是将创新技术和科学发现转化为下一代药物，有可能使严重未满足医疗需求的患者受益。

SR One leadership has worked together to build and invest in biotechnology companies for more than a decade. Working alongside the investment team, SR One’s venture partners bring deep operational experience to help company creation initiatives and support portfolio companies with financing and corporate strategies.

SR One领导层十多年来一直在合作建立和投资生物技术公司。SR One的风险投资合作伙伴与投资团队合作，带来丰富的运营经验，帮助公司创建计划，并为投资组合公司提供融资和公司战略支持。

SR One has offices in Redwood City, CA, and Philadelphia, PA, in the US and London in the UK. For more information, please visit www.srone.com..

SR One在加利福尼亚州红木城、美国宾夕法尼亚州费城和英国伦敦设有办事处。有关更多信息，请访问www.srone.com。。

About NEA

关于NEA

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has over $25 billion in assets under management as of December 31, 2023, and invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO.

New Enterprise Associates，Inc.（NEA）是一家全球风险投资公司，专注于帮助企业家在多个阶段、部门和地区建立转型型企业。NEA成立于1977年，截至2023年12月31日，其管理的资产超过250亿美元，并在公司生命周期的各个阶段（从种子期到IPO）投资于技术和医疗保健公司。

The firm's long track record of investing includes more than 270 portfolio company IPOs and more than 450 mergers and acquisitions. For more information, please visit www.nea.com..

该公司的长期投资记录包括270多家投资组合公司的首次公开募股和450多宗并购。欲了解更多信息，请访问www.nea.com。。

About Norwest Venture Partners

关于Norwest Venture Partners

Norwest Venture Partners is a global venture and growth equity investment firm managing more than $15.5 billion in capital. Since its inception, Norwest has invested in more than 700 companies and currently partners with more than 230 companies in its venture and growth equity portfolio. The firm invests in early- to late-stage businesses across key sectors with a focus on enterprise, consumer and healthcare.

Norwest Venture Partners是一家全球风险投资和成长股权投资公司，管理着超过155亿美元的资本。自成立以来，Norwest已投资了700多家公司，目前在其风险投资和成长股权投资组合中与230多家公司合作。该公司投资于关键行业的早期至晚期业务，重点关注企业、消费者和医疗保健。

The Norwest team offers a deep network of connections, extensive operating experience, and a wide range of impactful services to help CEOs and founders scale their businesses. Norwest has offices in Menlo Park and San Francisco, Calif.; Mumbai, India; and Tel Aviv, Israel. For more information, please visit www.nvp.com..

Norwest团队提供了深厚的人脉网络、丰富的运营经验和广泛的有影响力的服务，以帮助首席执行官和创始人扩大业务规模。Norwest在门罗公园和加利福尼亚州旧金山设有办事处。；印度孟买；以色列特拉维夫。有关更多信息，请访问www.nvp.com。。

About Delos Capital

关于Delos Capital

Delos Capital is a life sciences investment firm that partners with extraordinary teams pursuing breakthrough medicines that meaningfully improve the lives of patients. We are a collaborative, global team of seasoned biotech investors, company-builders, operators, and industry analysts, and we aim to serve the companies into which we invest by bringing both capital and substantive biotech expertise.

Delos Capital是一家生命科学投资公司，与非凡的团队合作，寻求突破性的药物，有意义地改善患者的生活。我们是一支由经验丰富的生物技术投资者、公司建设者、运营商和行业分析师组成的全球合作团队，我们的目标是通过引入资本和实质性的生物技术专业知识来为我们投资的公司服务。

We have designed, built, financed, and supported both novel platforms and approved medicines that strengthen hundreds of millions of lives across the world. Our global team is spread across offices in Cambridge, MA and in East Asia, allowing us to blend deep experiences operating at the epicenter of global biotech venture with proprietary insights into innovations from emerging biotech clusters.

我们设计、建造、资助和支持了新型平台和经批准的药物，这些平台和药物可以增强全世界数亿人的生命。我们的全球团队分布在剑桥、马萨诸塞州和东亚的各个办事处，使我们能够将在全球生物技术风险中心运营的丰富经验与对新兴生物技术集群创新的专有见解相结合。

Delos Capital currently manages three funds, with ~US$600 million in total capital under management. For more information, please visit www.deloscapital.com.Contact: .

Delos Capital目前管理着三只基金，管理的总资本约为6亿美元。有关更多信息，请访问www.deloscapital.com.Contact：。。

Investor and Media Contact:

投资者和媒体联系人：

Argot Partners

Argot合作伙伴

Zenas@argotpartners.com

Zenas@argotpartners.com